Roscovitine blocks leukocyte extravasation by inhibition of cyclin‐dependent kinases 5 and 9
BACKGROUND AND PURPOSE Roscovitine, a cyclin‐dependent kinase (CDK) inhibitor
that induces tumour cell death, is under evaluation as an anti‐cancer drug. By triggering …
that induces tumour cell death, is under evaluation as an anti‐cancer drug. By triggering …
Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5
S Goodyear, MC Sharma - Experimental and molecular pathology, 2007 - Elsevier
Roscovitine, a purine analogue, has been considered for the treatment of cancer. Anti-
cancer therapeutic efficacy is being evaluated in clinical trials. However, the mechanisms …
cancer therapeutic efficacy is being evaluated in clinical trials. However, the mechanisms …
Cyclin‐dependent kinase inhibitor drugs as potential novel anti‐inflammatory and pro‐resolution agents
AE Leitch, C Haslett, AG Rossi - British journal of pharmacology, 2009 - Wiley Online Library
The cyclin‐dependent kinase inhibitor (CDKi) drugs such as R‐roscovitine have emerged as
potential anti‐inflammatory, pharmacological agents that can influence the resolution of …
potential anti‐inflammatory, pharmacological agents that can influence the resolution of …
Roscovitine attenuates intimal hyperplasia via inhibiting NF-κB and STAT3 activation induced by TNF-α in vascular smooth muscle cells
M He, C Wang, J Sun, Y Liu, H Wang, J Zhao… - Biochemical …, 2017 - Elsevier
Roscovitine is a selective CDK inhibitor originally designed as anti-cancer agent, which has
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …
[HTML][HTML] Roscovitine in cancer and other diseases
Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells
IM Sroka, EH Heiss, L Havlicek, F Totzke, Y Aristei… - Molecular …, 2010 - ASPET
Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to the pathogenesis
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study
M Kolodziej, C Goetz, P Di Fazio… - Oncology …, 2015 - spandidos-publications.com
Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …
Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells
T Zhang, T Jiang, F Zhang, C Li… - Oncology …, 2010 - spandidos-publications.com
Roscovitine, a cyclin-dependent kinases (CDKs) inhibitor, has been reported to have anti-
tumor effects in some cancer cell lines by inducing apoptosis. However, the exact underlying …
tumor effects in some cancer cell lines by inducing apoptosis. However, the exact underlying …
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
K Bettayeb, N Oumata, A Echalier, Y Ferandin… - Oncogene, 2008 - nature.com
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …
R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy
A Dey, ET Wong, CF Cheok, V Tergaonkar… - Cell Death & …, 2008 - nature.com
Abstract Seliciclib (CYC202, R-Roscovitine) is a 2, 6, 9-substituted purine analog that is
currently in phase II clinical trials as an anticancer agent. We show in this study that R …
currently in phase II clinical trials as an anticancer agent. We show in this study that R …